Patents by Inventor Zdenek Zidek

Zdenek Zidek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polysubstituted pyrimidines inhibiting the formation of prostaglandin E2, a method of production thereof and use thereof
    Patent number: 11111219
    Abstract: The invention describes the pyrimidine-based compounds of the general formula I. Described compounds lower the production of the prostaglandin E2. In concentrations lowering production of this factor by 50%, these compounds have no negative effect on the cell viability and they are not cytotoxic. Furthermore, the method of production of the compounds of the general formula I is provided. A pharmaceutical composition comprising the polysubstituted pyrimidines according to the invention and the use of these compounds for the treatment of the inflammatory diseases are also provided.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: September 7, 2021
    Assignee: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I.
    Inventors: Viktor Kolman, Filip Kalcic, Zlatko Janeba, Zdenek Zidek
  • POLYSUBSTITUTED PYRIMIDINES INHIBITING THE FORMATION OF PROSTAGLANDIN E2, A METHOD OF PRODUCTION THEREOF AND USE THEREOF
    Publication number: 20200199080
    Abstract: The invention describes the pyrimidine-based compounds of the general formula I. Described compounds lower the production of the prostaglandin E2. In concentrations lowering production of this factor by 50%, these compounds have no negative effect on the cell viability and they are not cytotoxic. Furthermore, the method of production of the compounds of the general formula I is provided. A pharmaceutical composition comprising the polysubstituted pyrimidines according to the invention and the use of these compounds for the treatment of the inflammatory diseases are also provided.
    Type: Application
    Filed: May 23, 2018
    Publication date: June 25, 2020
    Applicants: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., USTAV EXPERIMENTALNI MEDICINY AV CR, V.V.I.
    Inventors: VIKTOR KOLMAN, Filip KALCIC, Zlatko JANEBA, Zdenek ZIDEK
  • Pyrimidine compounds inhibiting the formation of nitric oxide and prostaglandin E2, method of production thereof and use thereof
    Patent number: 8883798
    Abstract: The invention provides pyrimidine compounds of general formula (I), which reduce simultaneously the production of nitric oxide (NO) and prostaglandin E2 (PGE2). They have no negative effect on the viability of cells in concentrations decreasing the production of these factors by up to 50%; they are not cytotoxic. Furthermore, a method of preparation of the pyrimidine compounds of general formula (I), carrying 2-formamido group, a pharmaceutical composition comprising the substituted pyrimidine compounds according to the invention, and the use of these compounds for the treatment of inflammatory and cancer diseases are provided.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: November 11, 2014
    Assignees: Ustav Organicke Chemie a Biochemie Akademie Ved CR, V.V.I., Ustav Experimentalni Mediciny Akademie Ved CR, V.V.I.
    Inventors: Petr Jansa, Zdenek Zidek, Eva Kmonickova, Zlatko Janeba, Ludmila Hola
  • PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF
    Publication number: 20130324566
    Abstract: The invention provides pyrimidine compounds of general formula (I), which reduce simultaneously the production of nitric oxide (NO) and prostaglandin E2 (PGE2). They have no negative effect on the viability of cells in concentrations decreasing the production of these factors by up to 50%; they are not cytotoxic. Furthermore, a method of preparation of the pyrimidine compounds of general formula (I), carrying 2-formamido group, a pharmaceutical composition comprising the substituted pyrimidine compounds according to the invention, and the use of these compounds for the treatment of inflammatory and cancer diseases are provided.
    Type: Application
    Filed: February 27, 2012
    Publication date: December 5, 2013
    Applicants: USTAV EXPERIMENTALNI MEDICINY AKADEMIE VED CR, V.V.I., USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, V.V.I.
    Inventors: Petr Jansa, Antonin Holy, Zdenek Zidek, Eva Kmonickova, Zlatko Janeba